The COVID‐19 pandemic has disproportionally affected men.(1) Men infected with SARS‐CoV‐2 are more than twice as likely to be admitted to the intensive care unit (ICU).(2) This disparity in ICU admissions suggests the important role of androgens in COVID‐19 severity.(3) Previously, we reported that among 122 men hospitalized due to COVID‐19, 79% were diagnosed with androgenetic alopecia (AGA),(4) which is commonly treated with anti‐androgens. Anti‐androgens commonly used in the treatment of AGA such as finasteride, dutasteride, spironolactone, and bicalutamide could improve outcomes among men infected by SARS‐CoV‐2.
Anti‐androgens may protect against severe COVID‐19 outcomes: results from a prospective cohort study of 77 hospitalized men